MedTrace Logo

Stimulant Effects on Brain Activity

NCT02453698 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2015-05-25

No results posted yet for this study

Summary

The aim of this study is to investigate the effects of Methylphenidate on neural activity underlying inhibitory control and error monitoring in healthy adults. More specifically, the investigators aim to establish the baseline modulatory effect of Mehtlylphenidate on bottom-up and top-down aspects of these cognitive processes. This work will further our understanding of Attention Deficit Hyperactivity Disorder, Methylphenidate, and executive functioning.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Methylphenidate

oral dose of methylphenidate. The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, \& Gatley, 2002) and adults with ADHD (Aron et al., 2003). MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.

OTHER

Placebo

Lactose Placebo

Sponsors & Collaborators

  • The Hospital for Sick Children

    lead OTHER

Principal Investigators

  • Russell Schachar, MD · The Hospital for Sick Children, Toronto Canada

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-01-31
Completion
2012-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02453698 on ClinicalTrials.gov